borderline significantp = 0.076
Although sexual stage antibody prevalence was least common in those who did not develop gametocytes during follow-up (p<0.001), there was a borderline significant increase in the prevalence of both Pfs230 (p = 0.076) and Pfs48/45 antibodies (p = 0.14) between day 7, 28, and 84 in this group.